



PB-690-T100

Monoclonal Antibody to HLA-DR Pacific Blue™ conjugated (100 tests)

Clone: L243

Isotype: Mouse IgG2a

Specificity: The mouse monoclonal antibody L243 recognizes specifically HLA-DR molecules,

both peptide-loaded and empty.

Regulatory Status: RUO

Immunogen: Human B lymphocytes

Species Reactivity: Human, Non-Human Primates, Canine (Dog)

Preparation: The purified antibody is conjugated with Pacific Blue™ under optimum conditions.

The conjugate is purified by size-exclusion chromatography and adjusted for direct

use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis of human blood cells using 4

μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension.

The content of a vial (0.4 ml) is sufficient for 100 tests.

Expiration: See vial label

Lot Number: See vial label

Background: HLA-DR, a member of MHC class II glycoproteins, that bind intracellularly

processed peptides and present them to the Th cells, is composed of 36 kDa alpha chain and 27 kDa beta chain, both anchored in the plasma membrane. Together with other MHC II molecules HLA-DR plays a central role in the immune system. It is expressed on antigen-presenting cells (dendritic cells, B lymphocytes,

monocytes, macrophages).



PRODUCT DATA SHEET

References:

*Coral S, Pucillo C, Leonardi A, Fonsatti E, Altomonte M, Maio M: Triggering of HLA-DR antigens differentially modulates tumor necrosis factor alpha release by B cells at distinct stage of maturation. Cell Growth Differ. 1997 May;8(5):581-8.

*Cantin R, Martin G, Tremblay MJ: A novel virus capture assay reveals a differential acquisition of host HLA-DR by clinical isolates of human immunodeficiency virus type 1 expanded in primary human cells depending on the nature of producing cells and the donor source. J Gen Virol. 2001 Dec;82(Pt 12):2979-87.

*Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL, Kasper DL: Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J Immunol. 2002 Dec 1;169(11):6149-53.

*Muczynski KA, Ekle DM, Coder DM, Anderson SK: Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol. 2003 May;14(5):1336-48.

*Bouillon M, El Fakhry Y, Girouard J, Khalil H, Thibodeau J, Mourad W: Lipid raft-dependent and -independent signaling through HLA-DR molecules. J Biol Chem. 2003 Feb 28;278(9):7099-107.

*Swiatek-de Lange M, Rist W, Stahl HF, Weith A, Lenter MC: Comment on "MHC class II expression identifies functionally distinct human regulatory T cells". J Immunol. 2008 Mar 15;180(6):3625; author reply 3626.

*De Gassart A, Camosseto V, Thibodeau J, Ceppi M, Catalan N, Pierre P, Gatti E: MHC class II stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I down-regulation. Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3491-6.

*Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS: Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009 Aug;119(8):2143-59.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

This product is provided under an agreement between Molecular Probes, Inc. (a wholly owned subsidiary of Invitrogen Corporation), and Exbio Praha, a.s., and the manufacture, use, sale or import of this product may be subject to one or more U.S. patents, pending applications, and corresponding non-U.S. equivalents, owned by Molecular Probes, Inc. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity), including use in flow cytometry that does not utilize a bead based array, but excluding use in combination with microarrays or High Content Screening. The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Molecular Probes, Inc., Business Development, 29851 Willow Creek Road, Eugene, OR 97402, USA, Tel: (541) 465-8300. Fax: (541) 335-0504.